Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.65 |
| ▸ | MMP12 | P39900 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480043 | 1.00 | FFAR1 (0.65) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| Methyl 3-Phenylpropanoate SCHEMBL9424369 | 0.95 | TDP1 (0.61) | FFAR1MMP12TDP1HRH3HDAC2 | |
| SCHEMBL6308951 | 0.92 | FFAR1 (0.56) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL12646541 | 0.92 | PTPN1 (0.55) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL14340330 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL13943204 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL6308932 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL14732623 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL14733317 | 0.89 | FFAR1 (0.53) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL11887471 | 0.89 | FFAR1 (0.53) | FFAR1MMP12PTPN1TDP1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | FFAR1 3667/4885MMP12 2838/4885PTPN1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.